At Imago BioSciences, the science leads us to achieving the greatest patient benefit. While drug development rarely takes a straight path – it’s often marked by twists and turns – following the science is the only way to successfully find new treatments for malignant, life-threatening diseases of the bone marrow.
(noun) 1. The final and fully developed stage of an insect after its metamorphosis.
In this process of growth and development, the imago stage refers to the fully formed adult – one that has completed its transformation. In our view, the full maturation of a scientific idea or observation in medical research is when new treatments clinically prove their worth to patients. Anything less misses the mark.
With a new approach to treating malignant, life-threatening diseases of the bone marrow, our team follows the data to find the right applications of our drugs for patients.
Patients with essential thrombocythemia and myelofibrosis need new, safe and effective options. Our pipeline of therapies reflects our aim to address this immense need.
We see promise for patients through the lens of science. We’re evaluating our lead therapeutic candidate – bomedemstat – in clinical trials with the hope of providing a new potential treatment option.
The latest from Imago BioSciences
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc . (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today...
Read more- The study completed enrollment with 73 patients in April 2022 - - As of the data cutoff of 29 April 2022, bomedemstat demonstrated durability of response with 81% of patients achieving normalized platelet counts for at least 12 weeks - - 58% of patients treated with bomedemstat experienced...
Read more- As of the data cutoff date of 29 April 2022, in addition to improvements in the standard metrics of spleen volume reduction and symptom scores, long term treatment with bomedemstat showed: 52% had reductions in mutant allele frequencies, including ASXL1 85% of evaluable patients demonstrated...
Read more